



Proteomics International

LABORATORIES LTD

ASX/Media Release

5 February 2018

ASX code: PIQ

Proteomics International Options (ASX:PIQO) Exercised Options can be exercised up until 31 March 2018

Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) is pleased to announce that it has received \$111,250 from the exercise of options, and has today processed and issued the shares resulting from the exercise of those options.

The Directors, who are significant holders of PIQO Options, have indicated that it is also their intention to exercise the options held by them.

Managing Director, Dr Richard Lipscombe said, "We are delighted with the strong support of the Company's optionholders, particularly from those who have sought to exercise their right to convert their options well in advance of the expiry date."

PIQO optionholders are eligible to exercise their options up to 5pm (WST) on 31 March 2018. If all remaining PIQO options are exercised, the Company will receive a further \$3,335,121.

Proteomics International remains engaged with a number of potential strategic partners to bring the Promarker™ technology to market in Australia and overseas. It is possible that announcements may be made in the foreseeable future which could influence the price of PIQ shares and options.

The Directors wish to advise optionholders who intend to exercise their PIQO Options to act promptly, and not wait until the last possible time in case cleared funds are not received prior to the expiry date of 31 March 2018, which occurs on the Easter weekend. PIQO optionholders should also be aware that trading will cease in the PIQO Options on 23 March 2018.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Paul Hart [Investor Relations]
Director
Canary Capital
T: +61 421 051 474
E: phart@canarycapital.com.au

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. Proteomics International is recognised as a global leader in the field of proteomics. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.